Fundraising Fox

EpiVario

Philadelphia, US · Founded 2017 · Delaware corporation

EpiVario is a biotechnology company developing small-molecule ACSS2 inhibitors that target a neuroepigenetic process involved in long-term memory formation, aimed at treating PTSD and substance use disorders. Spun out of the University of Pennsylvania's Epigenetics Institute, it develops pharmacotherapeutics for memory-related psychiatric and addiction disorders.

BiotechHealthtechMental Health

Founders & leadership

EpiVario was founded in 2017 by Shelley Berger and Philipp Mews.

SBShelley Berger
Shelley BergerCo-Founder
PMPhilipp Mews
Philipp MewsCo-Founder
TKThomas Kim
Thomas KimExecutive
ESEric Schultenover
Eric SchultenoverNamed on SEC filing
MD
Michael DishowitzNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$1.1M disclosed across 4 rounds · 2018–2024

▶$125KraisedJan 2024 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric SchultenoverDirector
  • Yi-Yen ChenDirector
  • Thomas KimExecutive Officer, Director
Offering amount
$1.5M
Amount sold
$125K
Minimum investment
$25K
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$135KraisedSep 2022 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric SchultenoverDirector
  • Michael DishowitzDirector
  • Thomas KimExecutive Officer, Director
Offering amount
$1.5M
Amount sold
$135K
Proceeds to insiders
$48K
First sale
Aug 2022
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$233KraisedAug 2021 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas KimExecutive Officer, Director
  • Eric SchultenoverDirector
  • Michael DishowitzDirector
Offering amount
$1.3M
Amount sold
$233K
Minimum investment
$100K
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$599.5KraisedMar 2020 · 23 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas KimExecutive Officer, Director
  • Eric SchultenoverDirector
  • Michael DishowitzDirector
Offering amount
$750K
Amount sold
$599.5K
First sale
Sep 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Epi Biologics10 shared keywordsEpibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

Companies competing with EpiVario for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2022$260K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does EpiVario do?
EpiVario is a biotechnology company developing small-molecule ACSS2 inhibitors that target a neuroepigenetic process involved in long-term memory formation, aimed at treating PTSD and substance use disorders. Spun out of the University of Pennsylvania's Epigenetics Institute, it develops pharmacotherapeutics for memory-related psychiatric and addiction disorders.
Who founded EpiVario?
EpiVario was founded by Shelley Berger, Philipp Mews in 2017.
How much funding has EpiVario raised?
EpiVario has disclosed $1.1M raised across 4 rounds.
Where is EpiVario headquartered?
EpiVario is headquartered in Philadelphia, US.